Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

David Cella; Jennifer Evans; Marion Feuilly; Sebastian Neggers; Dirk Van Genechten; Jackie Herman; Mohid S. Khan

doi:10.1007/s12325-020-01600-x

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

David Cella^*, Jennifer Evans, Marion Feuilly, Sebastian Neggers, Dirk Van Genechten, Jackie Herman, Mohid S. Khan

^*Corresponding author for this work

Medical Social Sciences

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Introduction: Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) was conducted to investigate which characteristics beyond efficacy are most important in patient and healthcare practitioner (HCP) experience of LAN and OCT when used to treat acromegaly and NETs. Methods: MEDLINE, Embase, the Cochrane Library, and Database of Abstracts of Reviews of Effect were searched from database inception to January 2019 with terms for first-generation SSAs, NETs, acromegaly, preferences, decision-making, and human factors. Key congresses in 2016–2018 and SLR bibliographies were hand-searched. Two independent reviewers screened articles at title/abstract and full-text stage. Publications fulfilling pre-specified inclusion criteria reported patient or HCP perspectives of LAN or OCT, or any factors affecting treatment perspectives for NETs or acromegaly. Results: A total of 1110 unique records were screened, of which 21 studies were included, reporting from the perspectives of patients (n = 18) and/or HCPs (n = 9). Perspectives were collected using shared decision-making frameworks, questionnaires, informal patient opinion, and a Delphi panel. Where patient preference was specifically reported, LAN was preferred in 4/5 studies and OCT LAR in 1/5. Common factors underlying treatment experience included technical problems with injections and associated pain, emotional quality/anxiety of injections, time and convenience of treatment administration, and independence. Immediate aspects of injections appeared most important to patients, though the possibilities of extended dosing intervals and self-/partner-injection with LAN were also notable factors. Conclusions: Study outcomes favored LAN in this SLR, with factors surrounding injection administration most influential in treatment experience. The findings of this SLR provide a basis that could inform development of decision-making criteria, with patient and HCP treatment perspectives considered. Future studies should utilize a common method to report preference and associated drivers.

Original language	English (US)
Pages (from-to)	969-993
Number of pages	25
Journal	Advances in Therapy
Volume	38
Issue number	2
DOIs	https://doi.org/10.1007/s12325-020-01600-x
State	Published - Feb 2021

Funding

SN received speaker/consultancy fees from Pfizer and Ipsen, and research grants from Pfizer. DVG is Vice-President of the Belgian NET and MEN Association and board member of INCA. Both organizations receive grants from Ipsen and Novartis. No personal fees or renumeration have been received. The authors thank Daphne T. Adelman for her contributions to the analysis and interpretation of the data and critically revising drafts for important intellectual content. This study was sponsored by Ipsen. The study sponsor is also funding the journal’s Rapid Service and Open Access Fees. The authors thank Oliver Palmer, BSc (Hons), and Amelia Frizell-Armitage, PhD, of Costello Medical, UK, for medical writing and editorial support, which was sponsored by Ipsen in accordance with Good Publication Practice guidelines. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Substantial contributions to study conception and design: DC, JE, MF, SN, DVG, JH, MSK; substantial contributions to analysis and interpretation of the data: DC, JE, MF, SN, DVG, JH, MSK; drafting the article or revising it critically for important intellectual content: DC, JE, MF, SN, DVG, JH, MSK; final approval of the version of the article to be published: DC, JE, MF, SN, DVG, JH, MSK. This manuscript is based on work that has been previously presented at the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, in Barcelona, Spain, on March 11–13, 2020. DC received research grants and consulting honoraria from Ipsen and Novartis. DVG is Vice-President of the Belgian NET and MEN Association and board member of INCA. Both organizations receive grants from Ipsen and Novartis. No personal fees or renumeration have been received. JE has nothing to disclose. JH is the President of CNETS. The organization receives grants annually from Ipsen and Novartis. JH personally received one small honorarium from Novartis. MF was an employee of Ipsen at the time of these analyses. MF is now an employee of Bayer Pharmaceuticals. MSK received consulting honoraria and speaker fees from Ipsen and Novartis. SN received speaker/consultancy fees from Pfizer and Ipsen, and research grants from Pfizer. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. All data included in this manuscript have been reported in published studies.

Keywords

Acromegaly
Neuroendocrine tumors
Preference
Somatostatin analogs
Treatment perspectives

ASJC Scopus subject areas

Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12325-020-01600-x

Cite this

@article{e59f92f0bfdc4a48a18ff9b1dcde6d6f,

title = "Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review",

abstract = "Introduction: Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) was conducted to investigate which characteristics beyond efficacy are most important in patient and healthcare practitioner (HCP) experience of LAN and OCT when used to treat acromegaly and NETs. Methods: MEDLINE, Embase, the Cochrane Library, and Database of Abstracts of Reviews of Effect were searched from database inception to January 2019 with terms for first-generation SSAs, NETs, acromegaly, preferences, decision-making, and human factors. Key congresses in 2016–2018 and SLR bibliographies were hand-searched. Two independent reviewers screened articles at title/abstract and full-text stage. Publications fulfilling pre-specified inclusion criteria reported patient or HCP perspectives of LAN or OCT, or any factors affecting treatment perspectives for NETs or acromegaly. Results: A total of 1110 unique records were screened, of which 21 studies were included, reporting from the perspectives of patients (n = 18) and/or HCPs (n = 9). Perspectives were collected using shared decision-making frameworks, questionnaires, informal patient opinion, and a Delphi panel. Where patient preference was specifically reported, LAN was preferred in 4/5 studies and OCT LAR in 1/5. Common factors underlying treatment experience included technical problems with injections and associated pain, emotional quality/anxiety of injections, time and convenience of treatment administration, and independence. Immediate aspects of injections appeared most important to patients, though the possibilities of extended dosing intervals and self-/partner-injection with LAN were also notable factors. Conclusions: Study outcomes favored LAN in this SLR, with factors surrounding injection administration most influential in treatment experience. The findings of this SLR provide a basis that could inform development of decision-making criteria, with patient and HCP treatment perspectives considered. Future studies should utilize a common method to report preference and associated drivers.",

keywords = "Acromegaly, Neuroendocrine tumors, Preference, Somatostatin analogs, Treatment perspectives",

author = "David Cella and Jennifer Evans and Marion Feuilly and Sebastian Neggers and {Van Genechten}, Dirk and Jackie Herman and Khan, {Mohid S.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = feb,

doi = "10.1007/s12325-020-01600-x",

language = "English (US)",

volume = "38",

pages = "969--993",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Health Communications Inc.",

number = "2",

}

TY - JOUR

T1 - Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly

T2 - A Systematic Literature Review

AU - Cella, David

AU - Evans, Jennifer

AU - Feuilly, Marion

AU - Neggers, Sebastian

AU - Van Genechten, Dirk

AU - Herman, Jackie

AU - Khan, Mohid S.

PY - 2021/2

Y1 - 2021/2

N2 - Introduction: Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) was conducted to investigate which characteristics beyond efficacy are most important in patient and healthcare practitioner (HCP) experience of LAN and OCT when used to treat acromegaly and NETs. Methods: MEDLINE, Embase, the Cochrane Library, and Database of Abstracts of Reviews of Effect were searched from database inception to January 2019 with terms for first-generation SSAs, NETs, acromegaly, preferences, decision-making, and human factors. Key congresses in 2016–2018 and SLR bibliographies were hand-searched. Two independent reviewers screened articles at title/abstract and full-text stage. Publications fulfilling pre-specified inclusion criteria reported patient or HCP perspectives of LAN or OCT, or any factors affecting treatment perspectives for NETs or acromegaly. Results: A total of 1110 unique records were screened, of which 21 studies were included, reporting from the perspectives of patients (n = 18) and/or HCPs (n = 9). Perspectives were collected using shared decision-making frameworks, questionnaires, informal patient opinion, and a Delphi panel. Where patient preference was specifically reported, LAN was preferred in 4/5 studies and OCT LAR in 1/5. Common factors underlying treatment experience included technical problems with injections and associated pain, emotional quality/anxiety of injections, time and convenience of treatment administration, and independence. Immediate aspects of injections appeared most important to patients, though the possibilities of extended dosing intervals and self-/partner-injection with LAN were also notable factors. Conclusions: Study outcomes favored LAN in this SLR, with factors surrounding injection administration most influential in treatment experience. The findings of this SLR provide a basis that could inform development of decision-making criteria, with patient and HCP treatment perspectives considered. Future studies should utilize a common method to report preference and associated drivers.

AB - Introduction: Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature review (SLR) was conducted to investigate which characteristics beyond efficacy are most important in patient and healthcare practitioner (HCP) experience of LAN and OCT when used to treat acromegaly and NETs. Methods: MEDLINE, Embase, the Cochrane Library, and Database of Abstracts of Reviews of Effect were searched from database inception to January 2019 with terms for first-generation SSAs, NETs, acromegaly, preferences, decision-making, and human factors. Key congresses in 2016–2018 and SLR bibliographies were hand-searched. Two independent reviewers screened articles at title/abstract and full-text stage. Publications fulfilling pre-specified inclusion criteria reported patient or HCP perspectives of LAN or OCT, or any factors affecting treatment perspectives for NETs or acromegaly. Results: A total of 1110 unique records were screened, of which 21 studies were included, reporting from the perspectives of patients (n = 18) and/or HCPs (n = 9). Perspectives were collected using shared decision-making frameworks, questionnaires, informal patient opinion, and a Delphi panel. Where patient preference was specifically reported, LAN was preferred in 4/5 studies and OCT LAR in 1/5. Common factors underlying treatment experience included technical problems with injections and associated pain, emotional quality/anxiety of injections, time and convenience of treatment administration, and independence. Immediate aspects of injections appeared most important to patients, though the possibilities of extended dosing intervals and self-/partner-injection with LAN were also notable factors. Conclusions: Study outcomes favored LAN in this SLR, with factors surrounding injection administration most influential in treatment experience. The findings of this SLR provide a basis that could inform development of decision-making criteria, with patient and HCP treatment perspectives considered. Future studies should utilize a common method to report preference and associated drivers.

KW - Acromegaly

KW - Neuroendocrine tumors

KW - Preference

KW - Somatostatin analogs

KW - Treatment perspectives

UR - http://www.scopus.com/inward/record.url?scp=85099312762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099312762&partnerID=8YFLogxK

U2 - 10.1007/s12325-020-01600-x

DO - 10.1007/s12325-020-01600-x

M3 - Review article

C2 - 33432541

AN - SCOPUS:85099312762

SN - 0741-238X

VL - 38

SP - 969

EP - 993

JO - Advances in Therapy

JF - Advances in Therapy

IS - 2

ER -

Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint